[1]
Singh, N.; Pandurangan, A.; Rana, K.; Anand, P.; Ahmed, A.; Tiwari, A.K. Benzimidazole: A short review of their antimicrobial activity. Int. Curr. Pharm. J., 2012, 1(5), 119-127.
[2]
Nadeem, S.; Waquar, A.; Shamsher, A.; Ruhi, A.; Jain, S.; Azad, B.; Akhtar, J. Triazoles as potential bioactive agents. Int. J. Pharm. Sci. Rev. Res., 2011, 8(1), 161-169.
[3]
Monika, G.; Shivi, B.J. 1,3,4-Oxadiazole as antimicrobial agents: An overview. Chem. Pharm. Res., 2011, 3(3), 137-147.
[4]
Periti, P. Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: A mini review. J. Chemother., 1995, 7(3), 221-223.
[5]
Somisetti, N.R.; Ravisankar, T.; Latha, J.; Sudhakar, B.K. Synthesis, characterization and antimicrobial activity of novel biphenyl tetrazoles. Der. Pharma Chem., 2012, 4(3), 1093-1103.
[6]
Moni, S.; Prem, M.S.C. Dihydrofolate reductase as therapeutic target for infectious diseases: Opportunities and challenges. Future Med. Chem., 2012, 4(10), 1335-1365.
[7]
Bayomi, S.M.; Maarouf, A.R.; Abdel, A.N.I.; Ahmed, A.B.M. Synthesis, molecular modeling study, preliminary antitumor and antimicrobial evaluation of new benzimidazole derivatives. J. Am. Sci., 2013, 9(10), 42-48.
[8]
Chowdhury, S.F.; Guerrero, R.H.; Reto, B.R. Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase. J. Enzyme Inhib. Med. Chem., 2002, 17(5), 293-302.
[9]
Hassan, H.S.; El-Messery, S.M.; Al-Omary, F.A.; Al-Rashood, S.T.; Shabayek, M.I.; Abulfadl, Y.S. Habib, El-S.E.; El-Hallouty, S.M.; Fayad, W.; Mohamed, K.M.; El-Menshawi, B.S.; El-Subbagh, H.I. Non-classical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study. Eur. J. Med. Chem., 2013, 66, 135-145.
[10]
Cunha, E.F.; Ramalho, T.C.; Maia, R.E.; Fundao, I.D.; Janeiro, R.D.; Teodorico, C.R.; Ricardo, B.D. The search for new DHFR inhibitors: A review of patents, January 2001-February 2005. Expert Opin. Ther. Pat., 2005, 15(8), 967-986.
[11]
Yaseen, G.; Jadhav, S. Design, synthesis and antimicrobial activity of 2-mercaptobenzimidazole derivatives. Int. J. Pharma Bio Sci., 2010, 1(4), 281-286.
[12]
Lam, T.; Hilgers, M.T.; Cunningham, M.L.; Bryan, P.K.; Kirk, J.N.; Vickie, B.D.; Voon, O.; Michael, T.; Grayson, H.; Karen, J.Y.S.; John, F. Structure based design of new dihydrofolate reductase antibacterial agents: 7-(Benzimidazol-1yl)-2,4-diamino-quinazolines. J. Med. Chem., 2014, 57(3), 651-668.
[13]
Ohmeng, K.A.; Barbara, R. Receptor based design of novel dihydrofolate reductase inhibitors; benzimidazole and indole derivatives. J. Med. Chem., 1991, 34(4), 1383-1394.
[14]
Jing, X.; Zhu, Q.; Xu, F.; Ren, X.; Li, D.; Yan, C. Rapid one-pot preparation of 2-substituted benzimidazoles from esters using microwave conditions. Synth. Commun., 2006, 36, 2597-2602.
[15]
Tandon, V.K.; Kumar, M. BF3Et2 promoted one-pot expeditious and convenient synthesis of 2-substituted benzimidazoles and 3,1,5-benzoxadiazepines. Tetrahedron Lett., 2004, 45, 4185-4191.
[16]
Balalaie, S.; Hashemi, M.M.; Akhbari, M. A novel one-pot synthesis of tetrasubstituted imidazoles under solvent free conditions and microwave irradiation. Tetrahedron Lett., 2003, 44(8), 1709-1711.
[17]
Rastogi, R.; Sharma, S. 2-amino benzimidazoles in organic synthesis. Synthesis, 1983, 861-866.
[18]
Van Vliet, D.S.; Gillespie, P.; Scicinski, J. Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions. Tetrahedron Lett., 2005, 46, 6741-6746.
[19]
Hegedus, A.; Hell, Z.; Potor, A. Zeolite-catalyzed environmentally friendly synthesis of benzimidazole derivatives. Synth. Commun., 2006, 36, 3625-3635.
[20]
Lin, A.Y.; Isome, Y.; Stewart, E.; Liu, J.F.; Yohannes, D.; Yu, L. Microwave-assisted one step high-throughput synthesis of benzimidazoles. Tetrahedron Lett., 2006, 47, 2883-2892.
[21]
Bastien, D.; Ebert, M.C.C.J.C.; Forge, D.; Toulouse, J.; Kadnikova, N.; Perron, F.; Mayence, A.; Huang, T.L.; Eynde, J.V.; Pelletier, J.N. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase. J. Med. Chem., 2012, 55(7), 3182-3192.
[22]
Savel, J.; Durand, R. Dihydrofolate reductase inhibitors: New developments in antiparasitic chemotherapy. Expert Opin. Ther. Pat., 2001, 11(8), 1285-1290.
[23]
Yuthavonga, Y.; Tarnchompooa, B.; Vilaivanb, T. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc. Natl. Acad. Sci., 2012, 109(42), 16823-16828.
[24]
Kisliuk, R.L. The biochemistry of folates. In: Sirotnak, F.M.;
Ensminger, W.D.; Burchall, J.J.; Montgomery, J.A. (Eds). Folate
antagonists as therapeutic agents; New York: Academic Press. Sirotnak,
F.M. John Wiley and Sons, New York, 1984, Vol. 1, pp. 1-
55.
[25]
Adane, L.; Bhagat, S.; Arfeen, M. Design and synthesis of guanylthiourea derivatives as potential inhibitors of Plasmodium falciparum dihydrofolate reductase enzyme. Bioorg. Med. Chem. Lett., 2014, 24, 613-617.
[26]
Al-Rashood, S.T.; Hassan, S.G.; El-Messery, S.M.; Nagi, M.N.; Habib, E.E.; Al-Omary, F.A.M.; El-Subbagh, H.I. Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors. Bioorg. Med. Chem. Lett., 2014, 24, 4557-4567.
[27]
Blaney, J.M.; Hansch, C.; Silipo, C.; Vittoria, A. Structure activity relationship of dihydrofolate reductase inhibitors. Chem. Rev., 1984, 84, 333-407.
[28]
Schrodinger, L.L.C. (Maestro, version 10.2). New York, 2015.
[29]
El-Hamamsy, M.H.; Smith, A.W.; Thompson, A.S.; Threadgill, M.D. Structure based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg. Med. Chem., 2007, 15, 4552-4576.
[30]
Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28, 235-242.
[31]
Goncalves, A.D.; França, T.C.C.; Caetano, M.S.; Ramalho, T.C. Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: Reducing the computational cost in hybrid QM/MM methods. J. Biomol. Struct. Dyn., 2014, 32(2), 301-307.
[32]
Jimonet, P.; Audiau, F.; Barreau, M.; Blanchard, J.C.; Boireau, A.; Bour, Y.; Coleno, M.A.; Doble, A.; Doerflinger, G.; Huu, C.D.; Donat, M.H.; Duchesne, J.M.; Ganil, P.; Gueremy, C.; Honore, E.; Just, B.; Kerphirique, R.; Gontier, S.; Hubert, P.; Laduron, P.M.; Blevec, J.L.; Meunier, M.; Miquet, J.M.; Nemecek, C.; Pasquet, M.; Piot, O.; Pratt, J.; Rataud, J.; Reibaud, M.; Stutzmann, J.M.; Mignani, S. Riluzole series: Synthesis and in vivo “Antiglutamate” activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J. Med. Chem., 1999, 42(15), 2828-2843.
[33]
Tumelty, D.; Schwarz, M.K.; Needels, M.C. Solid phase synthesis of substituted benzimidazoles. Tetrahedron Lett., 1998, 39, 7467-7470.
[34]
Schuerman, R.A.; Tumelty, D. The reduction of aromatic nitro groups on solid supports using sodiumhydrosulfite (Na2S2O4). Tetrahedron Lett., 2000, 41, 6531-6535.
[35]
Bates, D.; Xia, M.J. A sulfoxide-based ring annelation approach to fused, many-membered ring N,S-heterocycles. Org. Chem., 1998, 63, 9190-9196.
[36]
Levai, A. Process for preparing 1,4-benzothiazepine derivatives. Pharmazie, 1980, 35, 680-681.
[37]
Bellamy, F.D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tetrahedron Lett., 1984, 25, 839-842.
[38]
Kugita, H.; Inoue, H.; Ikezaki, M.; Takeo, S. Novel reactions of nitroarenylketones with SnCl2. Chem. Pharm. Bull., 1970, 18, 2028-2037.
[39]
Hawser, S.; Lociuro, S.; Islam, K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol., 2006, 71, 941-948.
[40]
Lin, G.L.; Ednie, M.; Clark, C.; Smith, K.; Kosowska-Shick, S.; McGhee, P.; Dewasse, B.; Beachel, L.; Caspers, P.; Gaucher, B.; Mert, G.; Shapiro, S.; Appelbaum, P.C. Antistaphylococcal activities
of dihydrophthalazine dihydrofolates, a family of novel antibacterial
drugs by time-kill, abstract F1-3937. Abstr. 48th Annu. Intersci.
Conf. Antimicrob. Agents Chemother. (ICAAC).
[41]
Peppard, W.J.; Schuenke, C.D. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic resistant staphylococcal infections. Curr. Opin. Investig. Drugs, 2008, 9, 210-225.
[42]
Collins, C.H. Microbiological methods; Butterworths: London, 1964, p. 92.
[43]
Lorian, V. Antibiotics in laboratory medicine; Williams and Wikins: Baltimore, London, 1980, p. 1014.
[44]
CLSI approved standards M100-S15. Performance standards for antimicrobial susceptibility testing; clinical and laboratory standards institute; CLSI: Wayne, PA, 2008.
[45]
Wayne, P.A. CLSI approved standards M100-S15. Performance standards for antimicrobial susceptibility testing; clinical and laboratory standards institute; CLSI, 2008.
[46]
Murray, P.R.; Baron, E.J. Manual of clinical microbiology, 6th ed.;
Washington, D.C: ASM Press, 2007.
[47]
Guven, O.O.; Erdogan, T.; Goker, H.; Yildiz, S. Synthesis and antimicrobial activity of some novel phenyl and benzimidazole substituted benzyl ethers. Bioorg. Med. Chem. Lett., 2007, 17, 2233-2236.
[48]
Methods for dilution antimicrobial susceptibility tests for bacteria
that grow aerobically, 6th ed.; Approved standard. Document M7-
A6. Clinical and Laboratory Standards Institute, Wayne, PA, 2003.
[49]
Performance standards for antimicrobial susceptibility testing; 18th
informational supplement. Document M100-S19, Clinical Laboratory
Standards Institute, 2009.
